Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ziprasidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 13/20 | 0.98 |
| ▸ | DRD2 known ✓ | P14416 | 11/20 | 0.98 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 8/20 | 0.98 |
| ▸ | HTR7 | P34969 | 3/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | HTR6 | P50406 | 2/20 | 0.98 |
| ▸ | MTOR | P42345 | 1/20 | 0.98 |
| ▸ | RAB9A | P51151 | 1/20 | 0.98 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.98 |
| ▸ | HTR3B | O95264 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | PGR | P06401 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | GOT1 | P17174 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ziprasidone SCHEMBL30354044 | 1.00 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL122876 | 1.00 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL29594402 | 0.99 | KCNH2 (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL2978308 | 0.99 | KCNH2 (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL1164202 | 0.99 | KCNH2 (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL930539 | 0.99 | KCNH2 (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL2978306 | 0.99 | KCNH2 (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL6061373 | 0.99 | KCNH2 (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL10324884 | 0.99 | KCNH2 (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL122875 | 0.99 | KCNH2 (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1703898-A2 | ZIPRASIDONE FORMULATIONS | Alpharma, Inc. (US) | 2006-09-27 | — | — | EP | claimed |
| WO-2005065660-A2 | ZIPRASIDONE FORMULATIONS | ALPHARMA, INC. (US) | 2005-07-21 | — | — | WO | claimed |
| WO-2005065660-A3 | ZIPRASIDONE FORMULATIONS | ALPHARMA INC (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1703898-A2 | ZIPRASIDONE FORMULATIONS | Alpharma, Inc. (US) | 2006-09-27 | — | — | EP | disclosed |
| EP-1703898-A2 | ZIPRASIDONE FORMULATIONS | Alpharma, Inc. (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20050163858-A1 | Ziprasidone formulations | ACTAVIS GROUP PTC EHF | 2005-07-28 | — | — | US | disclosed |
| US-20050163858-A1 | Ziprasidone formulations | ACTAVIS GROUP PTC EHF | 2005-07-28 | — | — | US | disclosed |
| WO-2005065660-A2 | ZIPRASIDONE FORMULATIONS | ALPHARMA, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005065660-A2 | ZIPRASIDONE FORMULATIONS | ALPHARMA, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050163858-A1 | Ziprasidone formulations | SLC39A3, SLC39A11, SLC39A14 | HTR2A 17/4885DRD2 164/4885HTR2C 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.